The Early BPC-157 Trials (2002–2005): What the Abstracts Reported
In the early 2000s, BPC-157 was tested in two placebo-controlled human studies: a Phase I safety study in healthy volunteers and a 53-person trial in ulcerative colitis. Both were reported only as conference abstracts, and the colitis trial's reported results could not show a clear difference between BPC-157 and placebo.
What is known about these studies?
Both studies were identified through the US Food and Drug Administration's 2026 evidence review of BPC-157, which examined the compound's historical clinical record. They date from a period when BPC-157 was being developed as a potential medicine for inflammatory bowel disease.
2002–03 · Phase I rectal-enema safety study
According to the FDA's review, the most frequently reported side effects were headache and flatulence. Beyond that, little detail is publicly available.
2005 · Ulcerative colitis trial
The abstract reported that symptoms improved in both the BPC-157 and placebo groups. The reported difference between the groups could not show a clear effect of BPC-157, and the FDA's review concluded the available data were inadequate to support its efficacy and safety.
Why is abstract-only evidence weaker?
A conference abstract is a brief summary, usually written before full analysis is complete. It is not peer reviewed to the standard of a journal paper, key details of methods and results are missing, and there is no way to check the findings. Studies that produce convincing results are usually published in full; when a controlled trial from twenty years ago exists only as an abstract, that absence is itself informative.
What can we conclude?
These studies show that BPC-157 reached placebo-controlled human testing in the 2000s and was given to healthy volunteers and patients without serious reported harm in those small groups. They cannot support any conclusion about whether BPC-157 works, and the one controlled efficacy result that was reported could not show a difference from placebo.
What these studies do not prove
- They do not prove BPC-157 works: the reported colitis result could not show an effect.
- They do not establish safety beyond the small groups studied.
- Their details cannot be verified, because no full papers exist.
Research compound studied
BPC-157
The trials on this page investigated BPC-157, a synthetic peptide of 15 amino acids. Batch-tested BPC-157 with certificates of analysis is available from our catalogue.
Sold for laboratory research use only. Not for human consumption. Nothing on this page is a claim that any product treats or prevents any condition.
Where do these studies fit historically?
They are the earliest known human tests of BPC-157, from its development as a potential medicine for inflammatory bowel disease. That development programme did not lead to an approved medicine or further published trials, and nearly two decades passed before human research resumed with the small reports published from 2021 onwards. View all BPC-157 clinical trials and human studies →
Source
Details of both studies are taken from the US Food and Drug Administration's Pharmacy Compounding Advisory Committee briefing document on BPC-157 (2026), which reviewed the original conference abstracts (Veljaca et al., 2002–03; Ruenzi et al., 2005).
View the FDA briefing document →